Apogee TherapeuticsNASDAQ: APGE

Apogee Therapeutics stock has declined by 34% since a previous recommendation to buy, while the S&P 500 is up 7.7%. Apogee Therapeutics raised $420 million at $62/share, expanding their financial runway while advancing APG777 into Phase 2 trials. APG777, targeting atopic dermatitis and asthma, shows promise with less frequent dosing, aiming to compete with Sanofi's Dupixent.

Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.

Apogee Therapeutics, Inc. positive interim results achieved from Phase 1 study of APG777 for Atopic Dermatitis and Phase 2 study initiation and additional data expected in 1st half of 2024 and 2025, respectively. Company has potential to overcome other biologic drug companies targeting patients with inflammatory disorders by improving drug exposure by a significant margin. The global atopic dermatitis market is expected to reach $19.1 billion by 2030.

Apogee Therapeutics' APG777 shows promising Phase 1 results for AD, with a notably long half-life potentially reducing dosing frequency. APG777's efficacy and safety profiles justify Phase 2 trials, aiming to outperform competitors like Sanofi's Dupixent by offering less frequent dosing. Apogee boasts a strong liquidity position, with a cash runway of around 64 months, indicating minimal short-term financing needs.

SAN FRANCISCO and WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, asthma and other inflammatory and immunology (I&I) indications, today announced it will report interim results from the Phase 1 APG777 healthy volunteer trial on Tuesday, March 5, 2024. Following the announcement, the Company will host a conference call and webcast at 7:00am ET to discuss the results.

Review of Apogee Therapeutics' safety and pharmacokinetic data from phase 1 study using APG777 in healthy volunteers expected in mid-2024. Pending positive phase 1 safety and pharmacokinetic data using APG777, the initiation of a 16-week phase 2 study in atopic dermatitis patients is expected in 2024. The global atopic dermatitis market size is projected to reach $22.6 billion by 2031.

Following the Independence Day lull, the July IPO market warmed up with two sizable biotechs, joined by two blank check companies. Surf Air Mobility delayed its direct listing until later this month. In its second IPO attempt, Sagimet Biosciences priced a slightly upsized deal at the midpoint to raise $85 million at a $386 million market cap.

Apogee Therapeutics Inc will offer 15.625 million of its common shares in an initial public offering (IPO) that is expected to be priced between $15 and $17 per share, according to a US Securities and Exchange Commission (SEC) filing. The stock offering, which would value the company at as much as $774.5 million, is expected to net Apogee proceeds of between $228.2 million and $263.1 million, depending on whether the underwriters exercise in full their option to purchase additional shares.

Apogee Therapeutics, Inc. has filed proposed terms for a $250 million IPO. The firm is developing drug treatment candidates for atopic dermatitis, COPD and asthma. Apogee Therapeutics is still at preclinical stage of development, so the IPO is ultra-high-risk.